Clinical trials have demonstrated its efficacy in advanced HER2-positive tumors, leading to its FDA approval for HER2-positive GC/GEJ adenocarcinoma after prior exposure to trastuzumab with chemotherapy in the first-line setting. This evidence concerns the gene ERBB2 and adenocarcinoma.